


gamma-Secretase Modulators

Cat. No.:	HY-50900
CAS No.:	937812-80-1
Molecular Formula:	C ₂₆ H ₂₄ F ₃ N ₃ O ₃
Molecular Weight:	483.48
Target:	Amyloid-β
Pathway:	Neuronal Signaling
Storage:	4°C, stored under nitrogen
	* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 100 mg/mL (206.83 mM)

* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
	1 mM	2.0683 mL	10.3417 mL	20.6834 mL
	5 mM	0.4137 mL	2.0683 mL	4.1367 mL
	10 mM	0.2068 mL	1.0342 mL	2.0683 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
Solubility: ≥ 2.5 mg/mL (5.17 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (5.17 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.5 mg/mL (5.17 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

gamma-Secretase Modulators (Amyloid-β production inhibitor) is a Amyloid-β production inhibitor. gamma-Secretase Modulators is useful for Alzheimer's disease. IC50 value: Target: γ-secretase modulator

REFERENCES

- [1]. Watahiki H, Yagishita S, Futai E, Ishiura S. CTF1-51, a truncated carboxyl-terminal fragment of amyloid precursor protein, suppresses the effects of Aβ42-lowering γ-secretase modulators. *Neurosci Lett.* 2012 Sep 27;526(2):96-9. Epub 2012 Aug 23.

[2]. Wanngren J, Ottervald J, Parpal S, Portelius E, Strömberg K, Borgegård T, Klintonberg R, Juréus A, Blomqvist J, Blennow K, Zetterberg H, Lundkvist J, Rosqvist S, Karlström H. Second generation γ -secretase modulators exhibit different modulation of Notch β

[3]. Wagner SL, Tanzi RE, Mobley WC, Galasko D. Potential Use of γ -Secretase Modulators in the Treatment of Alzheimer Disease. *Arch Neurol*. 2012 Jul 16:1-4.

[4]. Bulic B, Ness J, Hahn S, Rennhack A, Jumpertz T, Weggen S. Chemical Biology, Molecular Mechanism and Clinical Perspective of γ -Secretase Modulators in Alzheimer's Disease. *Curr Neuropharmacol*. 2011 Dec;9(4):598-622.

[5]. Kretner, Benedikt; Fukumori, Akio; Gutsmedl, Amelie; Page, Richard M.; Luebbbers, Thomas; Galley, Guido; Baumann, Karlheinz; Haass, Christian; Steiner, Harald. Attenuated A β 42 Responses to Low Potency γ -Secretase Modulators Can Be Overcome for

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA